Opioid Use Disorder Market Size, Share, Opportunities, And Trends By Drug Type (Buprenorphine, Methadone, Naltrexone, Others), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Offline, Online), And By Geography - Forecasts From 2023 To 2028

  • Published : Nov 2023
  • Report Code : KSI061615587
  • Pages : 140

The opioid use disorder market is estimated to grow at a CAGR of 8.71% during the forecast period.

The continuous use of opioids that results in clinically significant distress or impairment is referred to as opioid use disorder. Opioid use disorder is characterized by an overwhelming need to use opioids. Hence, dependency and addiction are features of the most severe kind of opioid use disorder.  Opioid use disorder includes serious side effects that might result in impairment, relapses, and even death.

Market Drivers:

  • Growth chronic disease is driving the market growth

The rise in the incidence of chronic diseases including cancer, cardiovascular, and Orthopaedic diseases is primarily driving the opioid use disorders market growth. The incidence of surgical intervention rises as the number of chronic conditions increases. After surgery, opioid medications are used to alleviate pain. Even when the pain has subsided, this component can still lead to opiate drug addiction. Thus, the predicted increase in the frequency of chronic illnesses drives up demand for medications to treat opioid use disorders and propels the expansion of the opioid use disorder market.

  • Increase in awareness and overall financing

In the upcoming years, it is anticipated that the market dynamics for opioid use disorders will alter. The repeal of the DATA 2000 waiver and the limit on the number of patients that a doctor may treat with buprenorphine would completely alter the opioid use disorder market environment in the US and increase the usage of buprenorphine in the treatment environment. Additionally, it is anticipated that future legislative changes will increase patients with opioid use disorder access to MOUD and their usage in therapeutic settings.

  • Growing counselling and behavioral treatment

An evidence-based treatment for those with opioid use disorders is medication for opioid use disorder (MOUD), which is regarded as the gold standard of opioid use disorder treatment. In addition to medication, counseling, and behavioral treatments may be crucial components of opioid use disorder treatment, but they do not work by themselves. Additionally, medications are used to reduce cravings, lessen withdrawal symptoms, and avoid the euphoric effects of opioids. These medications enhance safety and lessen withdrawal symptoms, which may cause relapse or continued drug use but do not "cure" the sickness. Three FDA-approved medications are frequently used to treat opioid use disorders: methadone, buprenorphine, and naltrexone.

  • Increasing cases of opioid addiction

The general population is currently afflicted by a wide range of severe and chronic diseases, such as cancer, cardiovascular disease, pain from accidents, and other maladies. Patients who suffer from these illnesses commonly have chronic pain, which is typically managed with drugs, especially opioids. While the pain lessens, there is a greater chance that the patient may develop drug dependence. As a result of their abrupt discontinuation and growing dependency on certain drugs, the patient could experience withdrawal symptoms. This is the major growth driver for the opioid use disorder market.

  • Growing self-help programs

Self-help programs like Alcoholics Anonymous and Narcotics Anonymous are advocated for those with substance use problems, and these are anticipated to propel the opioid use disorder market growth. The integration of education, motivational enhancement, and self-help groups into individual and group counselling techniques in inpatient and outpatient programs aids patients in changing their perspectives on how opioids affect their lives, realizing that change is possible, and working to reduce behaviours that support illicit drug use while developing new behaviours that lessen drug-related problems.

  • Opioid treatment programs

The treatment services provided by opioid treatment programs (OTPs) are covered by Medicare and all state Medicaid programs. Using the code H0020 (Alcohol and/or drug services; methadone administration and/or service (supply of the drug by a licensed program), state Medicaid programs often pay for OTP services in daily or weekly bundles that include methadone doses, toxicology testing, nurse services, and counselling. Medicaid covers around 40% of all non-elderly individuals with opioid use disorder (OUD). These treatment programs are anticipated to propel the opioid use disorder treatment market.

North America is anticipated to dominate the opioid use disorder market

During the projected period, the North American opioid use disorder treatment market is anticipated to have a significant market share. The number of OWS diagnoses and treatments is rising steadily in the United States. The main causes of the rising use of opioids for the treatment of pain are chronic disorders, which are becoming more common. Additionally, big market participants like Indivior get the majority of their income from the American market.

Key manufacturers are focusing on product innovation

The top players in the opioid use disorder (OUD) market consistently choose effective tactics to strengthen their brand equity and foster the expansion of the worldwide market. Acquiring rival businesses and securing a profit for both entities is one such effective technique. For instance, Orexo AB worked with ApexB.io and Magellan Rx Management in February 2021 to do more studies using Modia.

Leading organizations working on the development of novel opioid use disorder medications include Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, and others. These medications may become available which is propelling the opioid use disorders market growth in the upcoming years.

Market Key Developments

  • In May 2023, For BRIXADI (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder, Braeburn submitted a revised NDA, which the FDA accepted.
  • In May 2023, according to Trevena, Inc., OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved by the FDA in the United States for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic, has been accepted by China's National Medical Products Administration (NMPA).

Opioid Use Disorder Market Scope:


Report Metric Details
Growth Rate CAGR of 8.71% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered Drug Type, Route of Administration, Distribution Channel, and Geography
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Mallinchrodt Pharmaceuticals, Viatris Inc., Pfizer Inc., Hikma Pharmaceuticals PLC
Customization Scope Free report customization with purchase



  • By Drug Type
    • Buprenorphine
    • Methadone
    • Naltrexone
    • Others
  • By Route of Administration
    • Oral
    • Parenteral
  • By Distribution Channel
    • Offline
    • Online
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

The global opioid use disorder market is estimated to grow at a CAGR of 8.71% during the forecast period.
Prominent key market players in the opioid use disorder market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, and Teva Pharmaceutical Industries Ltd., among others.
The opioid use disorder market has been segmented by drug type, route of administration, distribution channel, and geography.
The rise in the incidence of chronic diseases including cancer, cardiovascular disease, and orthopaedic diseases is primarily responsible for the opioid use disorders market growth.
North America is expected to hold a significant share of the opioid use disorder market.


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Research Process


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Market Opportunities

4.4. Porter’s Five Force Analysis

4.4.1. Bargaining Power of Suppliers

4.4.2. Bargaining Power of Buyers

4.4.3. Threat of New Entrants

4.4.4. Threat of Substitutes

4.4.5. Competitive Rivalry in the Industry

4.5. Industry Value Chain Analysis


5.1. Introduction

5.2. Buprenorphine

5.3. Methadone

5.4. Naltrexone

5.5. Others


6.1. Introduction

6.2. Oral

6.3. Parenteral


7.1. Introduction

7.2. Offline

7.3. Online


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1.  Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. Indivior PLC

10.2. Alkermes

10.3. Orexo AB

10.4. Titan Pharmaceuticals Inc.

10.5. Teva Pharmaceutical Industries Ltd.

10.6. Mallinckrodt Pharmaceuticals

10.7. Viatris Inc.

10.8. Pfizer Inc.

10.9. Hikma Pharmaceuticals PLC

Indivior PLC


Orexo AB

Titan Pharmaceuticals Inc.

Teva Pharmaceutical Industries Ltd.

Mallinckrodt Pharmaceuticals

Viatris Inc.

Pfizer Inc.

Hikma Pharmaceuticals PLC